{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-070944","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.895268+00:00","generated_at":"2026-06-07T11:26:20.832195+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024","bullets":["First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.","Safety, transcript splicing correction, and clinical outcome data at 5 mg/kg dose expected in 2024.","UK MHRA clearance obtained, enabling enrollment in third country (US, Canada, UK).","Trial to enroll ~24 adults; single ascending doses from 5 to 20 mg/kg with safety-based escalation.","CEO James McArthur calls dosing a significant milestone toward transformative therapy for DM1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-070944","json":"https://secwatch.observer/filing/0000950170-23-070944.json","markdown":"https://secwatch.observer/filing/0000950170-23-070944.md","text":"https://secwatch.observer/filing/0000950170-23-070944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/0000950170-23-070944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/pepg-20231218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:26:20.832195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}